RxDoctor Payments DataLook up a doctor →

Rim Tabbaa, MD

Internal Medicine · Broken Arrow, OKNPI 1467686717

Payments from drug & device makers

$12,453in general payments, 2019–2025

Across 713 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$1K
  • AstraZeneca$979
  • Boehringer Ingelheim$933
  • Novo Nordisk$794
  • Lilly USA, LLC$740
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$12,30599%
  • Education$1481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,453 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$63,546
Medicare patients
161
Services billed
1,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$55,364
JanuviaSitagliptin Phosphate45$41,239
OzempicSemaglutide23$28,363
JardianceEmpagliflozin18$24,920
VascepaIcosapent Ethyl60$21,865
Repatha SureclickEvolocumab16$19,697
XareltoRivaroxaban14$13,623
Breo ElliptaFluticasone/Vilanterol32$12,671
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,169
FarxigaDapagliflozin Propanediol15$8,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,719
Icosapent Ethyl15$6,343
LivaloPitavastatin Calcium17$5,985
Rosuvastatin Calcium155$5,735
Atorvastatin Calcium233$5,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$659$55,364112 claims
MerckJanuvia$110$41,23945 claims
Novo NordiskOzempic$794$28,36323 claims
Boehringer IngelheimJardiance$933$24,92018 claims
GSKBreo Ellipta, Trelegy Ellipta$1,360$20,38944 claims
AstraZenecaBreztri Aerosphere, Farxiga$979$18,67130 claims
Johnson & JohnsonXarelto$581$13,62314 claims
Kowa Pharmaceuticals America, Inc.Livalo$557$5,98517 claims
AbbVieSynthroid$1,074$3,74253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Broken Arrow

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →